Oncternal Therapeutics Inc. (ONCT): Don’t Rush To Buy This Stock

0
37

Oncternal Therapeutics Inc. (NASDAQ:ONCT) changes shares on Tuesday trading session, with a change of 2.08% or $0.06 shares. The trading starts at $2.89 and closed at $2.88 throughout the day. The trading session low price was $2.80 and day high was $2.98 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 64035.0 while its average volume is 69.78K. In other hand, the ONCT market cap reached to $53.24M.

On June 30, 2020, BRIEF-Oncternal Therapeutics Announces Orphan Drug Designations Of Cirmtuzumab Antibody For Treatment Of Mantle Cell Lymphoma And Chronic Lymphocytic Leukemia. According to the news reported on Reuters, * ONCTERNAL THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATIONS OF CIRMTUZUMAB ROR1 ANTIBODY FOR TREATMENT OF MANTLE CELL LYMPHOMA AND FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA Source text for Eikon: Further company coverage:

Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -5.16% and up 13.95% for month. Its quarterly performance was 14.40% above, while its half year performance is down -24.42%. ONCT yearly performance stood at negative -26.50% and fall -25.57% for year-to-date. Current recommendation for Oncternal Therapeutics Inc. is 3.00.

Earnings per share or EPS is an important financial measure, which defines the profitability of a company. ONCT EPS (TTM) for 12-month is -4.27. Its EPS Q/Q reached 50.60%. It has an EPS of 37.10% up for past five years and for the next five years will be down 0.00%.

Let’s take a look on the analyst recommendations on ONCT for the current month and previous month. For the current month, 0 of 1 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 1 as Hold. As compared with the previous month ratings, 0 analysts participate in stock recommendation. Out of 0, 0 rated it sell, 0 rated it as Buy and 0 as Hold Ratings. On the other hand, target price ranges from $10.50 – $10.50. Average target price for ONCT was reached at $10.50.

Creative Planning, Vanguard Group, Inc. (The) and Dowling & Yahnke LLC are the top three holders in Oncternal Therapeutics Inc. (ONCT) stock. On Jun 29, 2020, Creative Planning has 0.49 million shares which valued 1.39 million. On Mar 30, 2020, Vanguard Group, Inc. (The) owned 0.28 million shares which valued at 0.83 million. On Jun 29, 2020, Dowling & Yahnke LLC has a total of 0.15 million shares which valued at 0.43 million. In the end, Dowling & Yahnke LLC have 0.98% shares outstanding of Oncternal Therapeutics Inc. (ONCT) on Jun 29, 2020. The insider ownership moved to 5.90% and institutional holding shifted to 16.50%.

The company posted an EPS (TTM) of -4.27. Comparing with last year, the average estimated EPS was -0.62 which is lower than -0.22 which was posted for recent quarter EPS.

A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for ONCT fall -20.92% for period of 200 days. SMA for 50 days was 3.97% which is showing green signal, while SMA-20 was 12.24%. The moving average value for Oncternal Therapeutics Inc. (ONCT) is 31.21k and 0.20% for 200 and 50 days respectively.

Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in ONCT stock. On Jul 21, AKER HAZEL M, Legal Counsel, bought 41,972 trading shares at the cost of $2.38, which valued at 99998.0. On Jul 21, KISNER DANIEL L, Director, bought 10,000 shares at the cost of $2.38, with total shares of 10,000. On Jul 21, Shanghai Pharmaceutical (USA) , 10% Owner, bought 1,049,317 shares at the cost of 2.38. After this transaction, Shanghai Pharmaceutical (USA) total shares reached to 3,544,431 which valued at 2.5 million.